Viral hepatitis.
children
hepatitis B
hepatitis C
viral hepatitis
Journal
Journal of paediatrics and child health
ISSN: 1440-1754
Titre abrégé: J Paediatr Child Health
Pays: Australia
ID NLM: 9005421
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
14
05
2019
revised:
25
06
2019
accepted:
26
06
2019
pubmed:
19
7
2019
medline:
7
2
2021
entrez:
19
7
2019
Statut:
ppublish
Résumé
Hepatitis viruses A to E can cause abnormal liver function tests in children. Although, overall, they are relatively uncommon in children in Australia, epidemiology diagnosis and treatment modalities for these viruses have evolved over the last decade. This review provides an update on the diagnosis and treatment of viral hepatitis in children.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1038-1043Informations de copyright
© 2019 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).
Références
Donnan EJ, Fielding JE, Gregory JE et al. A multistate outbreak of hepatitis A associated with semidried tomatoes in Australia, 2009. Clin. Infect. Dis. 2012; 54: 775-81.
Raczniak GA, Thomas TK, Bulkow LR et al. Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children. Vaccine 2013; 31: 2152-5.
Blumberg BS. Polymorphisms of the serum proteins and the development of iso-precipitins in transfused patients. Bull. N. Y. Acad. Med. 1964; 40: 377-86.
Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014; 384: 2053-63.
MacLachlan JH, Allard N, Towell V, Cowie BC. The burden of chronic hepatitis B virus infection in Australia, 2011. Aust. N. Z. J. Public Health 2013; 37: 416-22.
Davis J, Weber M. A prospective audit of 215 newly arrived African refugees. J. Paediatr. Child Health 2007; 42: A11.
Paxton GA, Rice J, Davie G, Carapetis JR, Skull SA. East African immigrant children in Australia have poor immunisation coverage. J. Paediatr. Child Health 2011; 47: 888-92.
Bannister EG, Yuen L, Littlejohn M et al. Molecular characterization of hepatitis B virus (HBV) in African children living in Australia identifies genotypes and variants associated with poor clinical outcome. J. Gen. Virol. 2018; 99: 1103-14.
Jimenez G, Alex G, Paxton G, Connell TG, Hardikar W. B alert: Hepatitis B virus infection in children in Victoria. J. Paediatr. Child Health 2013; 49: E213-6.
Zhao LH, Liu X, Yan HX et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat. Commun. 2016; 7: 12992.
Jackson K, Locarnini S, Gish R. Diagnostics of hepatitis B virus: Standard of care and investigational. Clin. Liver Dis. 2018; 12: 5-11.
Sarkar M, Terrault NA. Ending vertical transmission of hepatitis B: The third trimester intervention. Hepatology 2014; 60: 448-51.
Dusheiko G, Wang B. Hepatitis B surface antigen loss: Too little, too late and the challenge for the future. Gastroenterology 2019; 156: 548-51.
Wirth S, Zhang H, Hardikar W et al. Efficacy and safety of peginterferon alfa-2a (40KD) in children with chronic hepatitis B: The PEG-B-ACTIVE study. Hepatology 2018; 68: 1681-94.
Yeo YH, Ho HJ, Yang HI et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: A systematic review and meta-analysis. Gastroenterology 2019; 156: 635.e9-46.e9.
Sokal EM, Paganelli M, Wirth S et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: Consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J. Hepatol. 2013; 59: 814-29.
Terrault NA, Lok ASF, McMahon BJ et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67: 1560-99.
Rosenthal P, Ling SC, Belle SH et al. Combination of entecavir/peginterferon alfa-2a in children with hepatitis B e antigen-positive immune tolerant chronic hepatitis B virus infection. Hepatology 2019; 69: 2326-37.
Zhu S, Zhang H, Dong Y et al. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study. J. Hepatol. 2018; 68: 1123-8.
Soriano V, Barreiro P, Benitez L, Peña JM, de Mendoza C. New antivirals for the treatment of chronic hepatitis B. Expert Opin. Investig. Drugs 2017; 26: 843-51.
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.
Raynes-Greenow C, Polis S, Elliott E et al. Childhood hepatitis C virus infection: An Australian national surveillance study of incident cases over five years. J. Paediatr. Child Health 2015; 51: 1115-20.
Hurtado CW, Golden-Mason L, Brocato M, Krull M, Narkewicz MR, Rosen HR. Innate immune function in placenta and cord blood of hepatitis C-Seropositive mother-infant dyads. PLoS One 2010; 5: e12232.
European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin. Infect. Dis. 2005; 41: 45-51.
Mohan P, Barton BA, Narkewicz MR et al. Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: A retrospective study. Hepatology 2013; 58: 1580-6.
González-Peralta RP, Langham MR Jr, Andres JM et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J. Pediatr. Gastroenterol. Nutr. 2009; 48: 630-5.
Rerksuppaphol S, Hardikar W, Dore GJ. Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J. Gastroenterol. Hepatol. 2004; 19: 1357-62.
Treloar C, Rance J, Backmund M. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clin. Infect. Dis. 2013; 57 (Suppl. 2): S51-5.
Nydegger A, Srivastava A, Wake M, Smith AL, Hardikar W. Health-related quality of life in children with hepatitis C acquired in the first year of life. J. Gastroenterol. Hepatol. 2008; 23: 226-30.
Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J. Gastroenterol. 2016; 22: 7824-40.
Hardikar W, Elliott EJ, Jones CA. The silent infection: Should we be testing for perinatal hepatitis C and, if so, how? Med. J. Aust. 2006; 184: 54-5.
Jonas MM, Balistreri W, Gonzalez-Peralta RP et al. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: Results from the pediatric study of hepatitis C (PEDS-C) trial. Hepatology 2012; 56: 523-31.
Balistreri WF, Murray KF, Rosenthal P et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017; 66: 371-8.
Murray KF, Balistreri WF, Bansal S et al. Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6-11. Hepatology 2018; 68: 2158-66.
Schwarz KB, Rosenthal P, Murray KF et al. Ledipasvir/Sofosbuvir for 12 weeks is safe and effective in children 3 to <6 years old with chronic hepatitis C virus infection. Hepatology 2019; https://doi.org/10.1002/hep.30830 (forthcoming).
Wirth S, Rosenthal P, Gonzalez-Peralta RP et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 2017; 66: 1102-10.
Abdel Ghaffar TY, El Naghi S, Abdel Gawad M et al. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C genotype 4. J. Viral Hepat. 2019; 26: 263-70.
Indolfi G, Hierro L, Dezsofi A et al. Treatment of chronic hepatitis C virus infection in children: A position paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J. Pediatr. Gastroenterol. Nutr. 2018; 66: 505-15.
Rizzetto M, Canese MG, Aricò S et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977; 18: 997-1003.
Özgenç F, Ecevit ÇÖ, Erdemir G, Sertöz R, Yağcı RV. Prevelance of hepatitis D co-enfection in children with hepatitis B infection: Cross-sectional analyses from Western Turkey. Turk. J. Gastroenterol. 2013; 24: 345-8.
Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin. Liver Dis. 2012; 32: 211-9.
Noureddin M, Gish R. Hepatitis delta: Epidemiology, diagnosis and management 36 years after discovery. Curr. Gastroenterol. Rep. 2014; 16: 365.
Rizzetto M. Targeting hepatitis D. Semin. Liver Dis. 2018; 38: 66-72.
Hoad VC, Seed CR, Fryk JJ et al. Hepatitis E virus RNA in Australian blood donors: Prevalence and risk assessment. Vox Sang. 2017; 112: 614-21.
Hoad VC, Gibbs T, Ravikumara M et al. First confirmed case of transfusion-transmitted hepatitis E in Australia. Med. J. Aust. 2017; 206: 289-90.
Shrestha MP, Scott RM, Joshi DM et al. Safety and efficacy of a recombinant hepatitis E vaccine. N. Engl. J. Med. 2007; 356: 895-903.
Zhu FC, Zhang J, Zhang XF et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: A large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895-902.